Venous Stents Market: By Technology (Iliac Vein Stent Technology, Wall Stent Technology), By Material (Nitinol, Elgiloy), By Indication (Chronic Deep Vein Thrombosis, Post-Thrombotic Syndrome (PTS), May-Thurner’s Syndrome, and Others), By Application (Leg, Chest, Abdomen, and Others), and Geography

venous stents market was valued at USD 1,981.8 million in 2023 and growing at a CAGR of 5.6%. The market is driven by the increasing prevalence of venous diseases such as deep vein thrombosis (DVT) and chronic venous insufficiency (CVI) due to the aging population, rising obesity rates, and increased sedentary lifestyles. As the prevalence of these diseases rises, so too will the demand for venous stents. The growing adoption of minimally invasive procedures of venous stenting offers several advantages over traditional surgery, such as shorter recovery times and less pain. As patients and physicians become more aware of the benefits of minimally invasive procedures, the demand for venous stents is expected to increase. There have been significant technological advancements in venous stents in recent years.

For instance, new stent designs have been developed that are more effective at preventing blood clots and improving blood flow. These advancements are expected to further drive the growth of the market. The venous stents market constraints hinder market growth, mainly by a lack of awareness, and reimbursement challenges. Reimbursement for venous stents can be challenging, as some private and public payers are reluctant to cover the costs of these procedures. This can limit the adoption of venous stents in some markets. There is a lack of awareness among some patients and physicians about the benefits of venous stenting. This can limit the use of these devices.

Venous Stents Market Key Developments:

• In May 2022, Becton Dickinson (BD) reinstated its Venovo venous stent in the U.S. market after a recall in May 2021. The Venovo stent, which was specifically designed for iliofemoral vein obstruction, had initially received FDA approval.
• In April 2023, Bentley Innomed Gmbh acquired Qmedics to expand the portfolio of self-expanding stents for peripheral endovascular procedures into the field of interventional radiology.